Abstract: The present invention relates to business methods for transplanting adult mesenchymal stem/progenitor and/or other regenerative cells ancillary to sports/entertainment/celebrity/performer medicine, athletic/entertainment/celebrity/performer performance contracts, including sports contracts or contract insurance policies in order to treat and/or prevent injuries to individuals, especially including athletes, musicians, singers, dancers, actors, entertainers, celebrities and/or performers who are subject to a risk of injury. The present methods may be used to reduce the time that an performance entertainer is injured and unable to participate in a particular physical activity such as a sport or other public entertainment setting and the likelihood that an injury to an performance entertainer will be of long duration and/or career ending.

Abstract: The present invention relates to including the invention in Key-Person, Term Life, or Critical Illiness Insurance policies to provide potential life-saving and health enhancements in addition to the death benefits covered under existing policies. The collection, processing and cryo-preservation of adult stem cells from any adult source, taken from peripheral blood, umbilical cord blood, bone marrow, adipose, heart, muscle, skin, nasal, liver, kidney, pancreas, testes, or other adult sources can also be used as a rider to insurance policies or to the in-benefits for the sale of products or services. The resulting method will substantially reduce the costs and extend premium payments for insurance companies as payouts for death benefits on Key-Person, Term Insurance, or Critical Illiness Insurance policies will be markedly reduced as therapies extend the life of the insured.

Abstract: The present invention relates to methods of reprogramming adult stem cells or stem cells obtained from umbilical or placental cord blood or more preferably, the placeta or umbilical cord tissue itself or the amniotic fluid or amnion. The resulting stem cells and methods of using these stem cells represent additional aspects of the present invention. Stem cells according to the present invention, especially neonic stem cells (those obtained/reprogrammed from neonate stem cells), represent great potential in duplicating embryonic stem cell research without utilizing embryonic stems cells which have raised ethical and moral issues. The stem cells of the present invention which are reprogrammed are obtained from adults or from neonates without causing injury or death to a fetus in the case of embryonic stem cells and are non-controversial. In this sense, the present invention avoids many of the legal, ethical or moral considerations which have complicated the use of embryonic stem cells.